Drugs / MDX2003
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT07249905 | Apr 2026 → Jan 2028 expected | Waldenstrom macroglobulinemia, follicular lymphoma, high grade B-cell lymphoma, primary mediastinal large B-cell lymphoma | ModeX Therapeutics, An OPKO Health Company | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MDX2003 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07249905 ↗ |
| Route | Intravenous | “MDX2003 intravenous infusion” NCT07249905 ↗ |